This is a repository copy of Bone area provides a responsive outcome measure for bone changes in short-term knee osteoarthritis studies.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/103446/

Version: Accepted Version

Article:

https://doi.org/10.3899/jrheum.151118

© 2016. This is an author produced version of a paper published in Journal of Rheumatology. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Bone area provides a responsive outcome measure for bone changes in short-term knee osteoarthritis studies

<table>
<thead>
<tr>
<th>Journal:</th>
<th>The Journal of Rheumatology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>2015-1118.R2</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Brief Communication</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>n/a</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Bowes, Michael; Imorphics, Maciewicz, Rose Waterton, John; University of Manchester, Hunter, David; University of Sydney, Northern Clinical School Conaghan, Philip; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine</td>
</tr>
<tr>
<td>Keywords:</td>
<td>Bone, Osteoarthritis, Knee</td>
</tr>
</tbody>
</table>
Bone area provides a responsive outcome measure for bone changes in short-term knee osteoarthritis studies

Michael A Bowes, Rose A Maciewicz, John C Waterton, David J Hunter, Philip G Conaghan

Abstract

Objective: This post-hoc study analyzed 3D bone area from an osteoarthritis (OA) cohort demonstrating no change in cartilage thickness.

Methods: 27 women with painful medial knee OA had MRI at 0, 3 and 6 months. Images were analysed using active appearance models.

Results: At 3 and 6 months the mean change in medial femoral bone area was 0.34% [95% CI 0.04, 0.64] and 0.61% [CI 0.32, 0.90]. 40% of subjects had progression > SDD at 6 months.

Conclusion: In this small cohort at high risk of OA progression, bone area changed at 3 and 6 months when cartilage morphometric measures did not.

Key Indexing Terms: Bone, Knee, Osteoarthritis

Name of department(s) and institution(s) to which the work should be attributed

1Imorphics, Manchester, UK
2Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca, UK
3Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
4Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Australia and Rheumatology Department, Royal North Shore Hospital.
Sources of support in the form of grants or industrial support

None

Initial, surnames, appointments and highest academic degrees of all authors

M.A. Bowes, PhD

D.J. Hunter, Florance and Cope Chair of Rheumatology, Professor of Medicine, PhD

R.A. Maciewicz, Chief Scientist, PhD

J.C Waterton, Professor of Translational Imaging, PhD

Corresponding author address/ request for reprint to:

Dr Mike Bowes

Imorphics

Kilburn House

Manchester Science Park

Manchester, UK

Phone: +44 161 2276613 Email: mike@imorphics.com

Running Head

OA bone area change
Introduction

There is an urgent need for treatments to arrest structural progression in osteoarthritis (OA).

However, we lack responsive measures (biomarkers) which could be used in early phase evaluation of investigational therapies. Radiography and magnetic resonance imaging (MRI) offer many structural biomarkers, but currently these require larger sample sizes and longer duration of treatment than would be ideal in a Phase 2 study.

Bone is integral to the OA pathological process and a number of bony pathologies including subchondral bone thickening, trabecular morphometry, bone marrow lesions and bone shape have been investigated (1). There is likely to be considerable interplay between the subchondral bone and cartilage (2). Changes in bone shape and area have been shown to be predictive biomarkers for the onset of knee osteoarthritis (3, 4), and can be accurately quantified using active appearance modelling (AAM), a form of statistical shape modelling that enables automatic segmentation. (Figure 1) (5, 6). Recent studies in large cohorts have shown that change in 3D bone area is specific for knee OA and more responsive than radiographic joint space width and cartilage thickness (7).

A previous study designed to assess the responsiveness of cartilage thickness in a small knee OA cohort enriched for known risk factors of progression including high BMI, female gender and varus alignment demonstrated no significant change in cartilage thickness at the group level in the medial femur or tibia at 3 or 6 months (8). The current post-hoc study analysed the changes in bone area of the femoral condyles in this cohort to determine the responsiveness of this novel bone biomarker.

Materials and Methods

29 participants were recruited in a multi-centre, non-randomized, observational cohort study at four sites in the USA (8). 27 females had knee pain, a body mass index (BMI) ≥ 25 kg/m², radiographic
evidence of medial OA, varus malalignment, and images at all timepoints, 2 did not have all images. A single knee was selected, being the knee with highest KL score, or the right knee if no difference.

MR images were acquired using 3T Siemens systems, using the dual echo steady state water excitation acquisition sequence (DESS-we), previously used in the Osteoarthritis Initiative (9). MR images were acquired at recruitment, with follow-up images at 1 week (providing a double baseline), 3 and 6 months. Ethics approval was obtained from the sites involved in the study and all participants gave informed consent.

Images were automatically segmented using AAMs of the femur, built using an unrelated training set (7), which has been shown to segment with point-to-surface accuracy of less than 1mm (10). Two area measures (mm$^2$) were extracted from the bone surface produced by the AAM: the medial and lateral femorotibial regions of the femur (Figure 1), which were found to be the most responsive regions in a larger study (7).

Repeat baseline MRI scans were acquired a week apart (8), allowing estimation of repeatability by calculation of root-mean-square coefficients of variation (CoV), and smallest detectable difference (SDD), defined as the mean of the differences ±1.96 standard deviations. Change over time was assessed using a paired t-test of the ratio of the value of each timepoint against the baseline value, using the geometric mean of the 2 baseline images. Spatial location of bone area change was visualised by colour change maps, and displayed on the mean bone shape (Figure 2).

**Results**

The mean age was 62 years (range 50 - 80). Mean BMI at baseline was 35 kg/m$^2$ (31 - 44); mean WOMAC pain score was 7 (1-12). Mean knee alignment was 0.4° (-1.9° to +6.3°) (varus positive); 12 of 27 were left knees. 19 knees were Kellgren Lawrence Grade 3; the remainder were Grade 2.

Repeatability for the MF region was 0.39% (CoV) and 1.1% (SDD), and for the LF region was 0.66% (CoV), 1.9% (SDD). At 3 months the mean change in MF bone area was 0.34% [95% confidence
interval (CI) (0.04, 0.64), \( p=0.03 \) and at 6 months 0.61\% \[ CI 0.32, 0.90, p=0.0002 \]; baseline MF area = 2291 mm\(^2\). In the LF region, the changes were not significant at 3 months 0.24\% \[ CI -0.17\%, 0.66, p=0.23 \], but became significant at 6 months 0.49\% \[ CI 0.18, 0.80, p=0.0021 \] (Figure 1); baseline = 1527 mm\(^2\). Standardised Response Mean (SRM) of MF at 3:6 months were 0.45:0.85 and for LF at 6 months was 0.66. There were no significant differences between the KL 2 and KL3 groups, for example, MF region changed 0.32 (\(-0.01,0.65\)) at 3 months, and 0.57 (0.25,0.89) in the KL3 group, and 0.34(-0.18,0.50) at 3 months, 0.63(0.5,0.76) at 6 months in the KL2 group (all values in percent).

Previously reported (3) cartilage thickness change was not significant at any time point, and showed no trend with time. Mean change at 3 months for medial femoral cartilage was \(-1.3\% \) [range -2.9, 0.3], at 6 months 0.8\% [range -1.4, 3.0]; baseline = 1.54 mm. Mean change at 3 months for medial tibial cartilage was 1.3\% [range -3.9, 1.7], at 6 months -1.0\% [range -3.2, 1.2]; baseline = 2.27 mm.

Graphs of change with time for each participant are shown in Figure 3, together with the SDD for each measure. Bone area measures showed increasing numbers of progressors (those with change greater than the SDD) with time, but progressors outnumbered regressors at each point. 41% of subjects progressed more than SDD using the MF bone area measure at 6 months (11 subjects), compared with 15\% who lost cartilage greater than SDD in the MT region (4 subjects).

The spatial pattern of change was similar to that reported in a larger study (7). Increase in area was seen in articulating tibiofemoral surfaces, together with a circumferential increase in bone area around the cartilage plate, in the osteophytic region (Figure 2).

**Discussion**

In this small, short-term study of people with OA knee selected for high risk of structural progression, 3D bone area using AAMs demonstrated change in 3 months for the medial femoral region, and for both femoral regions at 6 months. Previous analysis of this dataset did not
demonstrate significant change in cartilage thickness (1), one of the most promising MRI biomarkers of OA progression to date (11).

Though the participant numbers were small in this study, the change shows a clear trend in bone area change, with 3-month change about half that at 6 months. Rates of area change per bone region were also similar to those reported from a large OA longitudinal dataset, which showed annual change of 0.75% in the MF region, as compared to 1.2% in this study (3), further supporting the validity of these findings.

The structural endpoints in most clinical trials in the musculoskeletal area, such as those for rheumatoid arthritis where good treatments and patient responses are common, are driven by a few percent of progressors (change greater than SDD) because of the relationship between small changes and large measurement noise. This study is notable, both because significant change is detected in the population, but also because the change shows a clear trend with time, and is greater than SDD in a significant number of participants.

Power calculations, using an SRM of 0.85, the value for change in MF region at 6 months, assuming intervention had 50% reduction, one-sided, 80% power, L=0.05%, show that cohorts of ~80 persons would be needed for each arm of an intervention study.

Longitudinal change in bone area has been reported elsewhere (12, 13). These studies have primarily considered tibial rather than femoral bone, and use 2D methods of identification of area. The repeatability of AAMs resulted in an SDD of approximately 1% compared to 4% in these previous studies.

There are limitations to this work. It is reasonable to expect that there may be some relationship between changes in bone and cartilage, but no relationship was seen in this admittedly small study. While this analysis was based on an appropriately collected, well designed study, it does represent a post-hoc analysis. The MRI scanners and imaging sequences employed in this study were as used in
the Osteoarthritis Initiative (9). The images derived from these MRI scans were not optimised to
visualise bone, so further responsiveness may be possible with dedicated bone sequences. We have
only provided data on one 3D bone shape biomarker (bone area) and other measures, such as those
that measure other regions within the subchondral bone, may be more responsive.

This study compared bone area with one specific method of cartilage measurement; other methods,
and other variables such as volume may provide better responsiveness. However, we are not aware
of any method showing significant cartilage change in less than 30 people in 6 months.

In this small cohort selected for high risk of OA progression, bone area changed in an approximately
linear manner at 3 and 6 months from baseline. Bone area shows promise as a highly sensitive
biomarker of OA progression, detecting change when current imaging outcomes are unable to do so,
and provides a potential tool for small, short-duration, proof of concept studies, such as those with a
treatment likely to affect bone.

Acknowledgements

We would like to thank the investigators of the MiME Osteoarthritis Study: C.B. Eaton, C.K. Kwoh, J.
Samuels, A.P. Holmes and H. Mann.

References

1. Barr AJ, Campbell TM, Hopkinson D, Kingsbury SR, Bowes MA, Conaghan PG. A systematic
review of the relationship between subchondral bone features, pain and structural pathology in
peripheral joint osteoarthritis (accepted for publication). Arthritis Res Ther 2015
2. Goldring MB, Goldring SR. Articular cartilage and subchondral bone in the pathogenesis of
osteoarthritis. Ann NY Acad Sci 2010;1192:230-7
imaging-based three-dimensional bone shape of the knee predicts onset of knee osteoarthritis: data
from the osteoarthritis initiative. Arthritis Rheum 2013;65:2048-58
periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH
OA Biomarkers Consortium (accepted for publication). Ann Rheum Dis 2015
Figure 1: Automatic segmentation of MR images using active appearance models, and generation of anatomical regions

Each image is automatically segmented using active appearance models, which produces a bone surface for femur and tibia. An outline of the automated segmentation in one slice is illustrated (A). The mean bone surface from multiple femurs is presented anatomically in B. The mean bone surface is actually a triangulated mesh (C and D) in which each vertex represents an anatomically corresponded point, or landmark. The vertices contained within the chosen regions are coloured in red. Inset shows close up of landmarks indicating actual density of vertices. MF: medial femur, LF: lateral femur. The boundary of the MF and LF regions were defined as a line on the bone corresponding to the anterior edge of the medial or lateral meniscus in the mean model.

500x500mm (300 x 300 DPI)
Figure 2: Bone area change at 3 and 6 months
Graphs show change from baseline, using a pairwise Student’s t-test, with 95% confidence limits. Figure on right shows average change at each triangle in the mean bone shape at 6 months, expressed as percent of original area.)

231x190mm (300 x 300 DPI)
Figure 3: Individual change of bone area and cartilage thickness

Change from baseline was determined using pairwise t-tests, and is expressed as percentage of baseline value. Bone regions are as specified in Figure 1. Smallest detectable difference (SDD) was calculated from the double baseline results, and is shown as a dotted line on each graph. At the 6 month timepoint for the MF region, several of the lines are overlaid, making it difficult to see directly how many individuals have reached the SDD. The number of individuals with change greater or less than SDD at each timepoint are therefore shown in brackets.

209x190mm (300 x 300 DPI)
Bone area provides a responsive outcome measure for bone changes in short-term knee osteoarthritis studies.

Michael A Bowes¹, Rose A Maciewicz², John C Waterton³, David J Hunter⁴, Philip G Conaghan⁵

Abstract

Objective: This post-hoc study analyzed 3D bone area from an osteoarthritis (OA) cohort demonstrating no change in cartilage thickness.

Methods: 27 women with painful medial knee OA had MRI at 0, 3 and 6 months. Images were analysed using active appearance models.

Results: At 3 and 6 months the mean change in medial femoral bone area was 0.34% [95% CI 0.04, 0.64] and 0.61% [CI 0.32, 0.90]. 40% of subjects had progression > SDD at 6 months.

Conclusion: In this small cohort at high risk of OA progression, bone area changed at 3 and 6 months when cartilage morphometric measures did not.

Key Indexing Terms: Bone, Knee, Osteoarthritis

Name of department(s) and institution(s) to which the work should be attributed

¹Imorphics, Manchester, UK
²Respiratory, Inflammation, Autoimmunity IMED, AstraZeneca, UK
³Biomedical Imaging Institute, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK
⁴Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Australia and Rheumatology Department, Royal North Shore Hospital.
Sources of support in the form of grants or industrial support

None

Initial, surnames, appointments and highest academic degrees of all authors

M.A. Bowes, PhD

D.J. Hunter, Florance and Cope Chair of Rheumatology, Professor of Medicine, PhD

R.A. Maciewicz, Chief Scientist, PhD

J.C Waterton, Professor of Translational Imaging, PhD

Corresponding author address/ request for reprint to:

Dr Mike Bowes

Imorphics

Kilburn House

Manchester Science Park

Manchester, UK

Phone: +44 161 2276613 Email: mike@imorphics.com

Running Head

OA bone area change
Introduction

There is an urgent need for treatments to arrest structural progression in osteoarthritis (OA).

However, we lack responsive measures (biomarkers) which could be used in the early phase evaluation of investigational therapies. Radiography and magnetic resonance imaging (MRI) offer many structural biomarkers of structural change, but currently these require larger sample sizes and longer duration of treatment than would be ideal in a Phase 2 study of an investigational therapy.

Bone is integral to the OA pathological process and a number of bony pathologies including subchondral bone thickening, trabecular morphometry, bone marrow lesions and bone shape have been investigated (1). There is likely to be considerable interplay between the subchondral bone and cartilage (2). Changes in bone shape and area have been shown to be predictive biomarkers for the onset of knee osteoarthritis (3, 4), and can be accurately quantified using active appearance modelling (AAM), a form of statistical shape modelling that enables automatic segmentation (Figure 1) (5, 6). Recent studies in large cohorts have shown that change in 3D bone area is specific for knee OA and more responsive than radiographic joint space width and cartilage thickness (7).

A previous study designed to assess the responsiveness of cartilage thickness in a small knee OA cohort enriched for known risk factors of progression including high BMI, female gender and varus alignment demonstrated no significant change in cartilage thickness at the group level in the medial femur or tibia at 3 or 6 months (8). The current post-hoc study analysed the changes in bone area of the femoral condyles in this cohort to determine the responsiveness of this novel bone biomarker.

Materials and Methods

29 participants were recruited in a multi-centre, non-randomized, observational cohort study at four sites in the USA (8). 27 females had knee pain, a body mass index (BMI) ≥ 25 kg/m², radiographic evidence of medial OA, and varus malalignment, and images at all timepoints, 2 did not have all
images. A single knee was selected, being the knee with the highest KL score, or the right knee if no difference.

MR images were acquired using 3T Siemens systems, using the dual echo steady state water excitation acquisition sequence (DESS-we), previously used in the Osteoarthritis Initiative (9). MR images were acquired at recruitment, with follow-up images at 1 week (providing a double baseline), 3 months and 6 months. Ethics approval was obtained from the sites involved in the study and all participants gave informed consent.

Images were automatically segmented using AAMs of the femur, built using an unrelated training set (7), which has been shown to segment with point-to-surface accuracy of less than 1mm (10). Two area measures (mm²) were extracted from the triangulated bone surface produced by the AAM: the medial and lateral femorotibial regions of the femur (Figure 1), which were found to be the most responsive regions in a larger study (7).

In the original imaging of participants, repeat baseline MRI scans were acquired a week apart (8), allowing estimation of repeatability by calculation of root-mean-square coefficients of variation (CoV), and smallest detectable difference (SDD), defined as the mean of the differences ±1.96 standard deviations. Change over time was assessed using a paired t-test of the ratio of the value of each timepoint against the baseline value, using either the geometric mean of the 2 baseline images. The spatial location of bone area change was visualised by colour change maps, and displayed on the mean bone shape (Figure 2).

Results

The mean age was 62 years (range 50 - 80). Mean BMI at baseline was 35 kg/m² (range 31 - 44); mean WOMAC pain score was 7 (range 1-12). Mean knee alignment was 0.4° (range -1.9° to +6.3°) (varus positive), and 12 of 27 were left knees. 19 knees were Kellgren Lawrence Grade 3; the remainder were Grade 2.
Repeatability for the MF region was 0.39% (CoV) and 1.1% (SDD), and for the LF region was 0.66% (CoV) and 1.9% (SDD). At 3 months the mean change in MF bone area was 0.34% [95% confidence interval (CI) (0.04, 0.64), p=0.03] and at 6 months 0.61% [CI 0.32, 0.90, p=0.0002]; baseline MF area = 2291 mm$^2$. In the LF region, the changes were not significant at 3 months 0.24% [CI -0.17%, 0.66, p=0.23], but became significant at 6 months 0.49% [CI 0.18, 0.80, p=0.0021] (Figure 1); baseline = 1527 mm$^2$. Standardised Response Mean (SRM) of MF at 3:6 months were 0.45:0.85 and for LF at 6 months was 0.66. There were no significant differences between the KL 2 and KL 3 groups, for example, MF region changed 0.32 (-0.01,0.65) at 3 months, and 0.57 (0.25,0.89) in the KL 3 group, and 0.34(-0.18,0.50) at 3 months, 0.63(0.5,0.76) at 6 months in the KL 2 group (all values in percent). No significant differences were seen between KL 2 and 3 knees (data not shown).

Previously reported (3) cartilage thickness change was not significant at any time point, and showed no trend with time. Mean change at 3 months for medial femoral cartilage was -1.3% [range -2.9, 0.3], at 6 months 0.8% [range -1.4, 3.0]; baseline = 1.54 mm. Mean change at 3 months for medial tibial cartilage was 1.3% [range -3.9, 1.7], at 6 months -1.0% [range -3.2, 1.2]; baseline = 2.27 mm.

Graphs of change with time for each participant are shown in Figure 3, together with the SDD for each measure. Bone area measures showed increasing numbers of progressors (those with change greater than the SDD) with time, but progressors outnumbered regressors at each point. 41% of subjects progressed more than SDD using the MF bone area measure at 6 months (11 subjects), compared with 15% who lost cartilage greater than SDD in the MT region (4 subjects).

The spatial pattern of change was similar to that reported in a larger study (7). Increase in area was seen in articulating tibiofemoral surfaces, together with a circumferential increase in bone area around the cartilage plate, in the osteophytic region (Figure 2).

Discussion
In this small, short-term study of people with OA knee selected for high risk of structural progression, 3D bone area using AAMs demonstrated change in 3 months for the medial femoral region, and for both femoral regions at 6 months. Previous analysis of this dataset did not demonstrate significant change in cartilage thickness (1), one of the most promising MRI biomarkers of OA progression to date (11).

Though the participant numbers were small in this study, the change shows a clear trend in bone area change, with the 3-month change about half that at 6 months. Rates of area change per bone region were also similar to those reported from a large OA longitudinal dataset, which showed annual change of 0.75% in the MF region, as compared to 1.2% in this study (3), further supporting the validity of these findings.

The structural endpoints in most clinical trials in the musculoskeletal area, such as those for rheumatoid arthritis where good treatments and patient responses are common, are driven by a few percent of progressors (those change greater than SDD) because of the relationship between small changes and large measurement noise. In such trials, it is uncommon for the mean change of the population to exceed the SDD. This study is notable, both because significant change is detected in the population, but also because the change shows a clear trend with time, and is measurable greater than SDD in a significant number of participants.

Power calculations, using an SRM of 0.85, the value for change in MF region at 6 months, assuming intervention had 50% reduction, one-sided, 80% power, L=0.05%, show that cohorts of ~80 persons would be needed for each arm of an intervention study.

Longitudinal change in bone area has been reported elsewhere (12, 13). These studies have primarily considered tibial rather than femoral bone, and use 2D methods of identification of area. The repeatability of AAMs resulted in an SDD of approximately 1% compared to 4% in these previous studies.
There are limitations to this work. It is reasonable to expect that there may be some relationship between changes in bone and cartilage, but no relationship was seen in this admittedly small study. While this analysis was based on an appropriately collected, well designed study, it does represent a post-hoc analysis. The MRI scanners and imaging sequences employed in this study were as used in the Osteoarthritis Initiative (9). The images derived from these MRI scans were not optimised to visualise bone, so further responsiveness may be possible with dedicated bone sequences. We have only provided data on one 3D bone shape biomarker (bone area) and other measures, such as those that measure other specific sites of change within the subchondral bone, may be more informative.

This study compared bone area with one specific method of cartilage measurement; other methods, and other variables such as volume may provide better responsiveness. However, we are not aware of any method showing significant cartilage change in less than 30 people in 6 months.

In this small cohort selected for high risk of OA progression, bone area changed in an approximately linear manner at 3 and 6 months from baseline. Bone area shows promise as a highly sensitive biomarker of OA progression, detecting change when current imaging outcomes are unable to do so, and provides a potential tool for small, short-duration, proof of concept studies, such as those with a treatment likely to affect bone.

Acknowledgements

We would like to thank the investigators of the MiME Osteoarthritis Study: C.B. Eaton, C.K. Kwoh, J. Samuels, A.P. Holmes and H. Mann.

References